Sosei Group has been granted a patent for compounds acting as agonists of muscarinic M1 and M4 receptors, useful in treating diseases related to these receptors. The patent covers the compound of formula (1) and its salts, along with pharmaceutical compositions containing them. GlobalData’s report on Sosei Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sosei Group, was a key innovation area identified from patents. Sosei Group's grant share as of May 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Agonists of muscarinic m1 and m4 receptors
A recently granted patent (Publication Number: US11999745B2) discloses a compound of formula (1) and its various derivatives, including salts and pharmaceutically acceptable forms. The patent also covers pharmaceutical compositions containing the compound or its salts along with suitable excipients. Additionally, the patent claims methods for treating cognitive and psychotic disorders in subjects by administering the compound or its salts, with specific mention of disorders like Alzheimer's disease, dementia with Lewy bodies, and schizophrenia.
Furthermore, the patent extends to compounds of formula (2) and their salts, along with pharmaceutical compositions containing these compounds. Methods for treating cognitive and psychotic disorders in subjects using these compounds are also outlined, with a focus on disorders such as Alzheimer's disease, dementia with Lewy bodies, and schizophrenia. The patent emphasizes the potential use of the disclosed compounds in alleviating acute pain, chronic pain, neuropathic pain, and inflammatory pain in subjects, showcasing a broad spectrum of therapeutic applications for the claimed inventions.
To know more about GlobalData’s detailed insights on Sosei Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
